Lost your password?

Blogs about: Exelixis

Featured Blog

Director's Chair

bioventuresforglobalhealth wrote 2 months ago: I am very pleased to let you know that Carl Feldbaum has been elected chairman of the BVGH Board of … more →

Tags: Actelion, Bio, Biotech, Biotechnology Institute, carl feldbaum

Keryx: Another beneficiary of the ASCO-effect

Michael Becker wrote 6 months ago: By Michael D. Becker In my prior article, I highlighted the “ASCO-effect,” which relates to the fact … more →

Tags: Article, Biotechnology, pi3k, PFE, kerx, ONXX, NVS, mTOR, exel

Exelixis and sanofi-aventis sign global license agreement

silico wrote 6 months ago: Sanofi-aventis and Exelixis Inc have announced a global license agreement for XL147 and XL765 and a … more →

Tags: Alliances, Pharmaceuticals, Sanofi-Aventis

Exelixis and Boehringer Ingelheim partners for autoimmune diseases

silico wrote 6 months ago: Exelixis and Boehringer Ingelheim have announced that they have established an exclusive, worldwide … more →

Tags: Alliances, Boehringer Ingelheim

Boehringer Ingelheim partners with Exelixis

silico wrote 7 months ago: Exelixis and Boehringer Ingelheim have announced that they have established an exclusive, worldwide … more →

Tags: Alliances, Boehringer Ingelheim

Your Science or Technology is on the Cutting Edge. Are Your People?

davidschull wrote 7 months ago: As The Leadership Edge writes on its Web site, great science or technology alone doesn’t make … more →

Tags: Anadys Pharmaceuticals, The Leadership Edge, Leadership training, life sciences, Roche Pharmaceuticals

GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184

crimsoncanary wrote 1 year ago: GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exel … more →

Tags: GlaxoSmithKline, GSK, kinase, Licensing, met, ret, vegfr2, XL184

Exelixis PI3K Inhibitor XL147 effective in Phase I

crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K inhibitor XL147 to exhibit … more →

Tags: kinase, pi3k, XL-147, XL147

Exelixis PI3K/mTOR Inhibitor XL765 effective in Phase I

crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K/mTOR kinase inhbitor XL765 … more →

Tags: mTOR, Phase I, pi3k, XL-765, XL765

Exelixis Raf kinase inhibitor XL281 effective in Phase I

crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis RAF kinase inhbitor XL281 to sh … more →

Tags: kinase, raf, XL-281, XL281

Exelixis IGF-1R/Src inhibitor XL228 effective in Phase I

crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis’ IGF-1R/Src inhibitor  XL … more →

Tags: IGF-1R, Phase I, src, XL-228, XL228

Exelixis MET/VEGFR2/RET inhibitor XL184 effective in Phase I

crimsoncanary wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis MET/VEGFR2/RET inhbitor XL184 d … more →

Tags: met, ret, vegfr2, XL-184, XL184

WO/2008/124161

kinasepro wrote 1 year ago: Exel’s got Pi3K-a in combination: Reminds one of the XL-147 combo study. So thats XL-647 ?  I … more →

Tags: EGF, pi3k

Exelixis Submit Due Diligence Report for Cdc7 Inhibitor XL413 to BMS

crimsoncanary wrote 1 year ago: Exelixis has submitted data to BMS on CDC7 inhibitor XL413. BMS has 30 days to decide whether it wan … more →

Tags: bms, CDC7, XL413, XL-413, Bristol-Myers Squibb

Exelixis MET/RET/VEGFR2 inhibitor XL184 achieves proof of concept in cancer

crimsoncanary wrote 1 year ago: Exelixis have announced that its MET/RET/VEGFR2 inhibitor XL184 has achieved proof of concept in hem … more →

Tags: kinase, GSK, met, phase iii, vegfr2, ret, XL184, XL-184

Exelixis initiate Phase III trial of MET/RET/VEGFR2 inhibitor XL184 in Thyroid cancer

crimsoncanary wrote 1 year ago: Exelixis have initiated a phase III trial of MET/RET/VEGFR2 inhibitor XL184 for the treatment of med … more →

Tags: kinase, met, phase iii, vegfr2, ret, XL184, XL-184

Exelixis and GlaxoSmithKline Conclude Six-Year Discovery and Development Collaboration

crimsoncanary wrote 1 year ago: Exelixis and GlaxoSmithKline will conclude their six-year collaboration in October 2008. GSK will ha … more →

Tags: kinase, GSK, GlaxoSmithKline, Licensing

Exelixis begin Phase II trial of multikinase inhibitor XL184 in Glioblastoma Multiforme

crimsoncanary wrote 1 year ago: Exelixis are initiating a Phase II trial of XL184 for the treatment of Malignant Glioma … more →

Tags: kinase, multikinase, met, phase ii, vegfr2, ret

Exelixis begin Phase I trial of PI3K/mTOR inhibitor XL765 in Glioma

crimsoncanary wrote 1 year ago: Exelixis are initiating a Phase I trial of XL765, in combination with Temozolomide, for the treatmen … more →

Tags: kinase, pi3k, mTOR, Phase I, XL765, XL-765


Have your say. Start a blog.

See our free features →

Related Tags
All →

Follow this tag via RSS